Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany

Table 3 Annual direct outpatient treatment costs of metastatic TNBC

			Sacituzumab govitecan		Eribulin		Capecitabine		Vinorelbine
Drug Costs [8, 17,18,19]		Value in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR
Tumor medication				167,239.06		39,892.63		2,454.96		7,789.39
Preparation		81.00	32	2,592.00	32	2,592.00	0	-	48	3,888.00
Concomitant medication				3,414.02		3,163.23		146.88		146.88
TOTAL				173,245.08		45,647.86		2,601.84		11,824.27
Costs for medical services [20, 21]	GOP	Value in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR	Quantity	Costs in EUR
Basic flat rate	13,491	35.38	4	141.52	4	141.52	4	141.52	4	141.52
Additional flat rate	13,500	21.52	4	86.08	4	86.08	4	86.08	4	86.08
Medical therapy	13,502	19.94	4	79.76	4	79.76	4	79.76	4	79.76
Infusion	02100	7.55	0	-	32	241.60	0	-	48	362.40
Outpatient supervision (2 h)	01510	49.91	31	1,547.21	0	-	0	-	0	-
Outpatient supervision (4 h)	01511	98.24	1	98.24	0	-	0	-	0	-
Computed tomography	34,340	65.46	4	261.84	4	261.84	4	261.84	4	261.84
Laboratory
Blood count	32,120	0.50	52	26.00	52	26.00	52	26.00	52	26.00
Blood serum	32,056–32,079	2.50	12	30.00	12	30.00	12	30.00	12	30.00
Active tumor disease care	86,512	26.16	4	104.64	4	104.64	4	104.64	4	104.64
Oral therapy	86,520	96.79	0	-	0	-	4	387.16	0	-
Intravascular therapy	86,516	198.71	4	794.84	4	794.84	0	-	4	794.84
TOTAL				3,170.13		1,766.28		1,117.00		1,887.08
TOTAL COSTS				176,415.21		47,414.14		3,718.84		13,711.35

ISSN: 1478-7547